BIO-RAD LABORATORIES, INC. (BIO)
About BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $2.6B
- Net income
- $759.9M
- Total assets
- $10.6B
- Market cap
- $8.4B
- Gross margin
- 51.9%
- Operating margin
- 1.8%
- Net margin
- 29.4%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.6B
- Cost of revenue
- $1.2B
- Gross profit
- $1.3B
- Operating expenses
- $1.3B
- Operating income
- $47.2M
- Income tax
- $235.6M
- Net income
- $759.9M
- EPS (basic)
- $27.87
- EPS (diluted)
- $27.85
Balance sheet
- Total assets
- $10.6B
- Current assets
- $2.9B
- Total liabilities
- $3.1B
- Current liabilities
- $517.0M
- Shareholders’ equity
- $7.5B
Cash flow
- Operating cash flow
- $532.2M
- Investing cash flow
- -$189.7M
- Financing cash flow
- -$283.2M
- Net cash flow
- $59.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $8.4B
- P/E ratio
- 14.0
- EPS (diluted)
- $27.85
- Shares outstanding
- 21.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 29, 1980
Bio-rad Laboratories, Inc. (BIO) Stock Price
- Profitable — net income of $759.9M in FY2025.
- Revenue grew 1% from FY2020 to FY2025.
- Gross margin of 51.9%, net margin 29.4%.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 14.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BIO-RAD LABORATORIES, INC..
Write a review
News about BIO-RAD LABORATORIES, INC.
News & sentiment via Polygon.io
Bio-rad Laboratories, Inc.: frequently asked questions
Is Bio-rad Laboratories, Inc. an American company?
Yes — Bio-rad Laboratories, Inc. is an American company headquartered in Hercules, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Bio-rad Laboratories, Inc. headquartered?
Bio-rad Laboratories, Inc. is headquartered in Hercules, California, United States.
Is Bio-rad Laboratories, Inc. publicly traded?
Yes — Bio-rad Laboratories, Inc. is a publicly traded company. Its stock trades under the ticker symbol BIO on the NYSE.
What does Bio-rad Laboratories, Inc. do?
Bio-rad Laboratories, Inc. is an American Medical Devices company in the Health & Beauty sector.
